Plimoth Trust Co. LLC Boosts Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Plimoth Trust Co. LLC increased its stake in Johnson & Johnson by 4.6% during Q2, now holding 36,992 shares valued at approximately $5.65 million.
• Johnson & Johnson reported $2.77 EPS for the latest quarter, exceeding estimates, with revenue growth of 5.8% year-over-year, totaling $23.74 billion.
• Dividend declared at $1.30 per share represents an annualized yield of 2.8%, with a payout ratio of 55.61%.

Plimoth Trust Co. LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,992 shares of the company's stock after buying an additional 1,613 shares during the period. Johnson & Johnson comprises approximately 1.4% of Plimoth Trust Co. LLC's portfolio, making the stock its 15th largest position. Plimoth Trust Co. LLC's holdings in Johnson & Johnson were worth $5,651,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Apexium Financial LP boosted its holdings in shares of Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB increased its stake in shares of Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after purchasing an additional 6,566 shares in the last quarter. Joel Isaacson & Co. LLC increased its stake in shares of Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after acquiring an additional 4,816 shares in the last quarter. Finally, Range Financial Group LLC increased its position in shares of Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after acquiring an additional 2,529 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.4%

Shares of JNJ stock opened at $188.95 on Wednesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.92. The firm has a fifty day moving average price of $177.04 and a 200-day moving average price of $163.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $455.06 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson's payout ratio is presently 55.61%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JNJ. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an "overweight" rating in a report on Friday. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $189.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.